High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
51.02M
+15.64%
-0.565
-8.87%
52.79M
+31.24%
-0.525
-11.02%
61.66M
+38.53%
-0.290
-75.63%
Estimates Revision
The market is revising Upward the revenue expectations for Establishment Labs Holdings Inc. (ESTA) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by 26.56%.
Revenue Estimates for FY2025
Revise Upward
+0.09%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.5%
In Past 3 Month
Stock Price
Go Up
+26.56%
In Past 3 Month
7 Analyst Rating
0Wall Street analysts forecast ESTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESTA is 56.14 USD with a low forecast of 45.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
0Current: 41.790
Low
45.00
Averages
56.14
High
70.00
0Current: 41.790
Low
45.00
Averages
56.14
High
70.00
Mizuho
Anthony Petrone
Outperform
maintain
$58 -> $70
2025-07-16
Reason
Mizuho
Anthony Petrone
Price Target
$58 -> $70
2025-07-16
maintain
Outperform
Reason
Mizuho analyst Anthony Petrone raised the firm's price target on Establishment Labs to $70 from $58 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Citi
Neutral
maintain
$38 -> $47
2025-07-09
Reason
Citi
Price Target
$38 -> $47
2025-07-09
maintain
Neutral
Reason
Citi raised the firm's price target on Establishment Labs to $47 from $38 and keeps a Neutral rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.
Citi
Joanne Wuensch
Neutral
maintain
$38
2025-05-22
Reason
Citi
Joanne Wuensch
Price Target
$38
2025-05-22
maintain
Neutral
Reason
Citi analyst Joanne Wuensch kept a Neutral rating on Establishment Labs with a $38 price target while adding an "upside 90-Day short-term view." Establishment will host an investor meeting on June 12 and generally, stocks trade up into such events, even if it doesn't "hold" the price appreciation afterwards as positioning normalizes, the analyst tells investors in a research note.
BTIG
Buy
maintain
$62
2025-05-16
Reason
BTIG
Price Target
$62
2025-05-16
maintain
Buy
Reason
BTIG reiterates a Buy rating on Establishment Labs with a $62 price target following a transfer of coverage. The firm views the Motiva breast implant as a "disruptive technology" that is likely to replace current implants given its "unique appearance, natural feel and impressive safety profile." The industry has experienced relatively minimal design innovation and discouraging adverse event rates over many years, the analyst tells investors in a research note. BTIG believes Motivab s 40%-plus share in its more established markets is indicative of Establishment's potential to capture share from entrenched players in newer markets such as the U.S. and China.
Needham
Hold -> Buy
upgrade
$48
2025-05-14
Reason
Needham
Price Target
$48
2025-05-14
upgrade
Hold -> Buy
Reason
Needham upgraded Establishment Labs to Buy from Hold with a $48 price target. The firm says the easing of the trade war between the U.S. and China reduces its concern about Establishment's international business while Mia and Preserve should become more significant growth drivers outside the U.S. Management is bullish on the U.S. Motiva launch, and Needham has increased confidence that it can be a source of upside in 2025, the analyst tells investors in a research note. The firm thinks Establishment's upcoming investor day on June 12 is likely to be a positive catalyst for the shares. The stock's valuation is attractive considering the company's growth potential, contends Needham.
Needham
Mike Matson
Hold
Initiates
n/a
2025-04-14
Reason
Needham
Mike Matson
Price Target
n/a
2025-04-14
Initiates
Hold
Reason
Needham initiated coverage of Establishment Labs with a Hold rating and no price target. The company's U.S. Motiva launch should serve as a "major growth driver" and a potential source of upside while its minimally invasive procedures may expand the breast implant market, the analyst tells investors in a research note. However, the firm says Establishment's international business has been weak, and that it worries the trade war could weigh on its international growth.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Establishment Labs Holdings Inc (ESTA.O) is -22.41, compared to its 5-year average forward P/E of -31.72. For a more detailed relative valuation and DCF analysis to assess Establishment Labs Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-31.72
Current PE
-22.41
Overvalued PE
-13.35
Undervalued PE
-50.08
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-89.53
Current EV/EBITDA
-133.35
Overvalued EV/EBITDA
-5.48
Undervalued EV/EBITDA
-173.58
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
7.90
Current PS
5.64
Overvalued PS
10.60
Undervalued PS
5.20
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 348.78% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ESTA News & Events
Events Timeline
(ET)
2025-05-07
16:01:45
Establishment Labs reports Q1 EPS (70c), consensus (83c)
2025-05-07
16:00:41
Establishment Labs names Peter Caldini as CEO
2025-02-26 (ET)
2025-02-26
16:01:26
Establishment Labs reports Q4 EPS ($1.19), consensus (66c)
Sign Up For More Events
Sign Up For More Events
News
Preview
4.0
07-16BenzingaMizuho Maintains Outperform on Establishment Labs Hldgs, Raises Price Target to $70
Preview
4.0
07-10BenzingaCitigroup Maintains Neutral on Establishment Labs Hldgs, Raises Price Target to $47
Preview
4.0
05-14BenzingaThis PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Sign Up For More News
People Also Watch
FAQ
What is Establishment Labs Holdings Inc (ESTA) stock price today?
What is Establishment Labs Holdings Inc (ESTA)'s business?
What is the price predicton of ESTA Stock?
What is Establishment Labs Holdings Inc (ESTA)'s revenue for the last quarter?
What is Establishment Labs Holdings Inc (ESTA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Establishment Labs Holdings Inc (ESTA)'s fundamentals?
How many employees does Establishment Labs Holdings Inc (ESTA). have?